©Author(s) (or their employer(s)) 2026.
World J Clin Pediatr. Mar 9, 2026; 15(1): 111093
Published online Mar 9, 2026. doi: 10.5409/wjcp.v15.i1.111093
Published online Mar 9, 2026. doi: 10.5409/wjcp.v15.i1.111093
Table 1 Inclusion and exclusion criteria of the study
| Inclusion criteria | Exclusion criteria |
| Clinical or laboratory activity of IBD | Monogenic form of IBD requiring specific therapy (such as bone marrow transplantation, etс.) |
| Endoscopic activity | |
| History of ineffectiveness or intolerance of tumor necrosis factor-alpha blockers as monotherapy or in combination with immunosuppressors, and at least one more biological drugs with a different mechanism |
- Citation: Gabrusskaya T, Ulanova N, Shilova E, Volkova N, Kilina S, Kornienko E, Kostik M. Efficacy and safety of dual-targeted therapy in children with inflammatory bowel disease: Retrospective cohort study. World J Clin Pediatr 2026; 15(1): 111093
- URL: https://www.wjgnet.com/2219-2808/full/v15/i1/111093.htm
- DOI: https://dx.doi.org/10.5409/wjcp.v15.i1.111093